uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026)
uniQure (QURE) recorded quarterly Non-Current Deferred Tax Liability of $7.8 million in Q1 2026, down 2.15% quarter-over-quarter from $8.0 million in Q4 2025, and up 6.24% on a YoY basis from $7.3 million in Q1 2025.
uniQure (QURE) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
uniQure's Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $7.8 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 6.24% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $7.8 million (up 6.24% YoY), while the FY2025 annual figure was $8.0 million, up 13.12% from the prior year.
- Non-Current Deferred Tax Liability was $7.8 million for Q1 2026 at uniQure, down from $8.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $11.3 million in Q1 2022 to a low of $4.9 million in Q3 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $7.8 million across 5 years, with a median of $7.6 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability slumped 42.77% in 2023, then jumped 55.11% in 2024.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $8.3 million in 2022, then slipped by 8.65% to $7.5 million in 2023, then decreased by 6.63% to $7.0 million in 2024, then climbed by 13.12% to $8.0 million in 2025, then decreased by 2.15% to $7.8 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $7.8 million (Q1 2026), $8.0 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | uniQure | 2.88 Bn | 2.88 Bn | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.80 Mn |
| Mar 31, 2026 | 7.80 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Dec 31, 2025 | 7.97 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | 7.96 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Mar 31, 2025 | 7.34 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Dec 31, 2024 | 7.04 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Sep 30, 2024 | 7.63 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Jun 30, 2024 | 7.32 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Mar 31, 2024 | 7.38 Mn |
| Dec 31, 2023 | 7.54 Mn |
| Dec 31, 2023 | 7.54 Mn |